Our Science

Interferon β

Interferon beta (IFN-β) is a naturally occurring protein, which orchestrates the body's antiviral responses. Viruses, including coronaviruses, have evolved mechanisms which suppress natural IFN-β production, thereby helping the virus evade the immune system.

Inhaled Interferon β

In the laboratory, IFN-β has been shown to protect cells from infection with a broad range of respiratory viruses that cause lower respiratory illness including highly pathogenic coronavirus strains, including MERS-CoV, SARS-CoV and SARS-CoV-2, the virus which causes COVID-19.

Synairgen has developed a formulation of IFN-β (SNG001) for direct delivery to the lungs via inhalation that is being investigated as a treatment for COVID-19 patients.

Host-directed antivirals strengthen the cell’s antiviral defences, so they are better able to fight off the virus.

Not all antivirals are the same

Watch this short animation to learn the difference between host-directed antivirals and directing acting antivirals.

Programmes & Clinical Trials

Synairgen's primary focus is developing inhaled interferon beta to meet the urgent need for the treatment of COVID-19.